Is Day One Biopharmaceuticals, Inc. overvalued or undervalued?
As of July 30, 2024, Day One Biopharmaceuticals, Inc. is considered risky and overvalued due to significant negative financial metrics and a year-to-date return of -43.09%, underperforming the S&P 500's 12.22%.
As of 30 July 2024, the valuation grade for Day One Biopharmaceuticals, Inc. has moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued given its significant negative metrics, including a Price to Book Value of 1.52, an EV to Sales ratio of 1.58, and an alarming ROCE of -2922.95%. In comparison, SAGE Therapeutics, Inc., a peer in the same industry, has a more favorable EV to EBITDA of -0.5626, highlighting the challenges faced by Day One.The stock has underperformed against the S&P 500 across multiple time frames, with a year-to-date return of -43.09% compared to the S&P 500's 12.22%. This stark contrast reinforces the notion that Day One Biopharmaceuticals is currently overvalued in the market.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
